NBIX Neurocrine Biosciences, Inc.
$138.40
Neurocrine Biosciences, Inc. (NBIX) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is $1.99 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.9% since its last earnings release on July 30, 2026.
Neurocrine Biosciences Beat Expectations, Raises Guidance
Thursday, July 30, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs $1.99
Rev est $1.04B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$155.36
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Held By 10 ETFs, by dollar flow
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- BMED iShares Health Innovation Active ETF
- BMED iShares Health Innovation Active ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
- IBRN iShares Neuroscience and Healthcare ETF
- IBRN iShares Neuroscience and Healthcare ETF
Charts powered in part by Lightweight Charts™ by TradingView.